Patent · US Active

Drug combinations to treat multiple myeloma

US11065240B2 · kind B2 · utility

2Cited by
22References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 5, 2015
Grant dateJul 20, 2021
Priority date—
Expiry dateAug 5, 2035

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.